Eptinezumab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Eptinezumab
Eptinezumab: Known uses and market status in Canada
Summary
All candidates produced by the TxGNN model for Eptinezumab that can be traced to a source are already known uses, so there is currently no new predicted indication. The one known use listed below belongs to the same disease category as an approved indication. It is not itself listed as approved.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| migraine with brainstem aura | migraine |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02542269 | VYEPTI | Valid | |
| 02510839 | VYEPTI | Valid |
Safety Considerations
Please refer to the package insert for safety information.
Two recent observational studies in the literature examined class-level safety signals for CGRP inhibitors: glaucoma risk and cerebrovascular events (ischaemic stroke/TIA). These are worth reviewing in any follow-up safety assessment.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.